Evolving Landscape for Rare Biomarkers in Non-Small Cell Lung Cancer

Posted 2025-04-10 11:23:16

196

The lung cancer therapeutics market has been significantly reshaped by the discovery and targeting of rare biomarkers for non-small cell lung cancer (NSCLC), particularly MET exon 14 skipping alterations. These rare genomic alterations have led to the development of targeted therapies, dramatically improving patient outcomes and transforming the lung cancer biomarker market.

Until the First-ever Approval of Capmatinib (Novartis), How NSCLC Patients with MET Exon 14 Skipping Alterations Were Treated?

Before the approval of Capmatinib (Tabrecta), NSCLC patients with MET exon 14 skipping alterations were treated with conventional chemotherapy or immunotherapy, which offered limited benefits. These patients often had poor prognoses due to lack of targeted treatment. The identification of biomarkers for NSCLC, such as MET exon 14, created an opportunity for more personalized approaches.

Launch Price of Capmatinib Vs Tepotinib?

Capmatinib (Tabrecta), developed by Novartis, was the first MET inhibitor to receive FDA approval in May 2020. The Tabrecta price and Tabrecta cost vary by region, but in the U.S., it is estimated at around $17,000 per month. Tepotinib, marketed as Tepmetko by Merck KGaA, followed closely with FDA approval in 2021. The Tepmetko cost or Tepmetko price is estimated slightly lower, ranging around $14,000–$15,000 monthly, depending on the dosage.

Expected Forecast of Capmatinib Vs. Tepotinib?

Both Capmatinib and Tepotinib are projected to see steady growth in the met inhibitors for lung cancer market. Analysts anticipate that Capmatinib Novartis will maintain a competitive edge due to its first-mover advantage, but Merck’s biomarker-focused strategy in non-small cell lung cancer (Merck biomarker non-small cell lung cancer) could narrow the gap. By 2030, both drugs are expected to play crucial roles in a growing niche within the biomarkers for non-small cell lung cancer segment.

What Next?

With evolving biomarkers for NSCLC, emerging therapies are being developed to further target rare genetic mutations. As precision medicine expands, competition in the lung cancer biomarker market is expected to intensify, offering new hope and treatment options for NSCLC patients globally.